Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 70 HER2-positive Breast Cancer 15 Carcinoma, Non-Small-Cell Lung 6 HER2 Positive Metastatic Breast Cancer 4 Breast Diseases 4 Brain Neoplasms 4 HER2 Positive Breast Cancer 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Salivary Gland Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Solid Tumor 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumor × pyrotinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡